

Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein

Cat. No. MHC-HM424

Description

Source	Recombinant Human HPV16 E7(HLA-A*02:01) Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and YMLDLQPET peptide.
Accession	P04439-1(HLA-A*02:01)&P61769(B2M)&YMLDLQPET peptide
Molecular Weight	The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.

Assay Data


Bis-Tris PAGE



Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data



The purity of Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer is greater than 95% as determined by SEC-HPLC.